Eli Lilly and Company, Johnson & Johnson, AbbVie, Novo Nordisk A/S, and Merck & Co., Inc. are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that research, develop, manufacture, or sell prescription medicines and related products. Investors may buy them to gain exposure to the healthcare sector, while weighing factors such as drug-trial results, patents, regulation, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE:LLY traded up $2.12 during trading hours on Monday, hitting $1,445.62. The stock had a trading volume of 1,297,145 shares, compared to its average volume of 2,949,839. The company has a 50 day simple moving average of $1,242.25 and a two-hundred day simple moving average of $1,110.30. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,475.25. The firm has a market capitalization of $1.36 trillion, a price-to-earnings ratio of 46.92, a P/E/G ratio of 1.73 and a beta of 0.40.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of Johnson & Johnson stock traded down $0.79 during trading on Monday, hitting $284.96. The stock had a trading volume of 2,379,985 shares, compared to its average volume of 7,927,020. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $195.90 and a 12 month high of $290.25. The firm has a market cap of $685.98 billion, a price-to-earnings ratio of 43.22, a P/E/G ratio of 2.82 and a beta of 0.22. The business's 50-day moving average is $266.97 and its 200 day moving average is $249.85.
Read Our Latest Research Report on JNJ
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded up $1.47 during midday trading on Monday, hitting $296.50. 1,518,667 shares of the company's stock were exchanged, compared to its average volume of 6,276,410. AbbVie has a 52-week low of $190.75 and a 52-week high of $302.93. The stock has a 50-day moving average price of $275.51 and a two-hundred day moving average price of $240.91. The company has a market cap of $524.09 billion, a P/E ratio of 51.08, a PEG ratio of 1.34 and a beta of 0.20.
Read Our Latest Research Report on ABBV
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
NYSE NVO traded up $0.25 during trading on Monday, reaching $41.88. The company's stock had a trading volume of 9,705,785 shares, compared to its average volume of 16,293,447. The firm has a fifty day moving average of $40.09 and a 200 day moving average of $43.34. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The stock has a market capitalization of $186.99 billion, a PE ratio of 10.56, a P/E/G ratio of 1.43 and a beta of 0.70. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.84 and a quick ratio of 0.64.
Read Our Latest Research Report on NVO
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of MRK traded down $1.18 during trading hours on Monday, reaching $146.58. 2,121,191 shares of the company's stock traded hands, compared to its average volume of 10,515,910. The stock has a market cap of $361.37 billion, a PE ratio of 151.14, a price-to-earnings-growth ratio of 6.77 and a beta of 0.13. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The firm's 50 day simple moving average is $146.16 and its 200-day simple moving average is $128.61. Merck & Co., Inc. has a 12 month low of $92.11 and a 12 month high of $156.92.
Read Our Latest Research Report on MRK
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.